Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease

Purpose of review Chronic obstructive pulmonary disease (COPD) is a disease state characterized by airflow limitation that is usually progressive. In addition, an abnormal inflammatory response of the lungs to noxious particles or gases can be seen throughout the airways, parenchyma, and pulmonary vasculature. So far, anti-inflammatory medications (eg, inhaled corticosteroids) have failed to show a major effect on the decline of lung function in COPD patients. Novel anti-inflammatory therapies such as selective phosphodiesterase 4 (PDE4) inhibitors are in clinical development. Their potential role in the management of COPD is described in this review. Recent findings Some of the selective PDE4 inhibitors have demonstrated in vitro and in vivo anti-inflammatory activity on cells commonly linked to airway inflammation in COPD, such as neutrophils. While these agents seem to offer only a modest improvement in lung function compared with other bronchodilators, their anti-inflammatory effects appear to provide some substantial benefits in reducing exacerbations and improving health-related quality of life. Summary Based on the available data, the second generation of selective PDE4 inhibitors will likely provide additional therapeutic options for the management of COPD. These agents may become an important tool in the treatment of this disease, since they target three important components of COPD: airway obstruction, inflammation, and structural changes.

[1]  C. Gleiter,et al.  Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg , 2004 .

[2]  E. Bateman,et al.  Long-term Safety of Roflumilast in the Treatment of Chronic Obstructive Pulmonary Disease , 2004 .

[3]  P. Barnes,et al.  Prospects for new drugs for chronic obstructive pulmonary disease , 2004, The Lancet.

[4]  R. Murdoch,et al.  Lack of Pharmacokinetic Interactions Between Cilomilast and Theophylline or Smoking in Healthy Volunteers , 2004, Journal of clinical pharmacology.

[5]  J. Hogg,et al.  Pathophysiology of airflow limitation in chronic obstructive pulmonary disease , 2004, The Lancet.

[6]  J. Donohue.  Therapeutic responses in asthma and COPD. Bronchodilators. , 2004, Chest.

[7]  M. Pruniaux,et al.  Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. , 2004, Life sciences.

[8]  A. Vignola.  PDE4 inhibitors in COPD F a more selective approach to treatment , 2004 .

[9]  G. Hoyle,et al.  Lymphoid tissue and emphysema in the lungs of transgenic mice inducibly expressing tumor necrosis factor-alpha. , 2004, American journal of respiratory cell and molecular biology.

[10]  N. Tzanakis,et al.  Inflammatory cell profiles and T‐lymphocyte subsets in chronic obstructive pulmonary disease and severe persistent asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[11]  U. Egerland,et al.  Anti-Inflammatory Potential of the Selective Phosphodiesterase 4 Inhibitor N-(3,5-Dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), in Human Cell Preparations , 2004, Journal of Pharmacology and Experimental Therapeutics.

[12]  R. Zuwallack,et al.  Theophylline and Phosphodiesterase Inhibitors in COPD , 2003 .

[13]  K. Rabe,et al.  Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). , 2003, Pulmonary pharmacology & therapeutics.

[14]  E. R. Sutherland,et al.  Airway inflammation in chronic obstructive pulmonary disease: comparisons with asthma. , 2003, The Journal of allergy and clinical immunology.

[15]  I. Pavord,et al.  Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. , 2003, American journal of respiratory and critical care medicine.

[16]  N. Hoefgen,et al.  In Vivo Efficacy in Airway Disease Models of N-(3,5-Dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic Acid Amide (AWD 12-281), a Selective Phosphodiesterase 4 Inhibitor for Inhaled Administration , 2003, Journal of Pharmacology and Experimental Therapeutics.

[17]  Hisham S. Elbatarny,et al.  Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. , 2003, Molecular pharmacology.

[18]  P. Barnes,et al.  Chronic obstructive pulmonary disease • 12: New treatments for COPD , 2003, Thorax.

[19]  J. Bousquet,et al.  Effect of cilomilast (Ariflo) on TNF-α, IL-8, and GM-CSF release by airway cells of patients with COPD , 2003, Thorax.

[20]  P. Barnes.  Theophylline: new perspectives for an old drug. , 2003, American journal of respiratory and critical care medicine.

[21]  M. Houslay,et al.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. , 2003, The Biochemical journal.

[22]  D. Spina.  Theophylline and PDE4 inhibitors in asthma , 2003, Current opinion in pulmonary medicine.

[23]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[24]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[25]  Peter Reid,et al.  Roflumilast Altana Pharma. , 2002, Current opinion in investigational drugs.

[26]  S. Jin,et al.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Robertson,et al.  Localization of phosphodiesterase-4 isoforms in the medulla and nodose ganglion of the squirrel monkey , 2001, Brain Research.

[28]  G. Cassali,et al.  Effects of inhibition of PDE4 and TNF‐α on local and remote injuries following ischaemia and reperfusion injury , 2001, British journal of pharmacology.

[29]  D M Essayan,et al.  Cyclic nucleotide phosphodiesterases. , 2001, The Journal of allergy and clinical immunology.

[30]  C. Brambilla,et al.  Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study , 2001, The Lancet.

[31]  R. Pauwels,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. , 2001, American journal of respiratory and critical care medicine.

[32]  J. Barsig,et al.  In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. , 2001, The Journal of pharmacology and experimental therapeutics.

[33]  A. Hatzelmann,et al.  Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE 4 Inhibitor Roflumilast in Vitro , 2001 .

[34]  M. Minnicozzi,et al.  Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia. , 2001, Pulmonary pharmacology & therapeutics.

[35]  M. Wjst,et al.  Margarine consumption and allergy in children. , 2001, American journal of respiratory and critical care medicine.

[36]  P. Barnes,et al.  Chronic obstructive pulmonary disease. , 2000, The New England journal of medicine.

[37]  P. Barnes,et al.  Mechanisms in COPD: differences from asthma. , 2000, Chest.

[38]  S. Christensen,et al.  Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. , 1999, Pulmonary pharmacology & therapeutics.

[39]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[40]  E. Sutherland,et al.  Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. , 1958, The Journal of biological chemistry.